Stockreport

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer [Yahoo! Finance]

MAIA Biotechnology, Inc.  (MAIA) 
PDF CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on d [Read more]